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Extracapsular Lymph Node Involvement Is a Negative
Prognostic Factor After Neoadjuvant Chemoradiotherapy in
Locally Advanced Esophageal Cancer
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Delphine Trousse, MD,* Anne Marie Tasei, MD,‡ Laetitia Dahan, MD,§ Christophe Doddoli, MD,*
Roger Guidicelli, MD,* Pierre Fuentes, MD,* Jean Francois Seitz, MD,§ and Pascal Thomas, MD*
Introduction: To assess prognosis depending on whether lymph
node involvement (LNI) is intracapsular or with extracapsular
breakthrough in patients with a locally advanced esophageal cancer
treated with neoadjuvant chemoradiation and surgery.
Methods: Ninety-four consecutive patients with an esophageal
cancer staged IIB (n  17) and III (n  77) received neoadjuvant
chemoradiation followed by transthoracic esophagectomy with two-
field lymphadenectomy. Histology was squamous cell carcinoma
(n  46) and adenocarcinoma (n  48). Neoadjuvant therapy
consisted of association of 5-fluorouracil/cisplatin concomitantly
with a 45-Gy radiation therapy. Disease-free survival (DFS) exclud-
ing the in-hospital mortality was analyzed according to the nodal
status and the invaded/resected lymph node ratio (LNR). Clinical
factors affecting survival or predictors of extracapsular invasion
were investigated by multivariate analysis.
Results: Five-year DFS rates were 46, 36, and 11% in N0 patients
(n 56), intracapsular LNI patients (n 18), and extracapsular LNI
patients (n  10), respectively (p  0.002). Intracapsular LNI
patients with an LNR 0.1 (n  12) had a 5-year DFS rate similar
to N0 patients (44 versus 46%, p 0.95). Intracapsular LNI patients
with an LNR 0.1 (n  6) had a DFS rate similar to extracapsular
LNI patients (18 versus 11%, p  0.69). Multivariate analysis
revealed that the sole independent factor affecting DFS was the
extracapsular LNI (HR  3.9, p  0.026). The number of invaded
LN seemed to be the sole significant predictive factor for the
development of ECLNI (HR  2.39, p  0.008).
Conclusion: After neoadjuvant chemoradiotherapy, there was a
significant difference on DFS depending on whether LNI was
intracapsular or extracapsular. Extracapsular invasion seems to be an
independent negative prognostic factor affecting survival, and its
presence is related to the number of invaded LN.
Key Words: Esophagectomy, Esophageal cancer, Chemoradiother-
apy, Neoadjuvant treatment, Lymph node ratio, Extracapsular lymph
node involvement.
(J Thorac Oncol. 2009;4: 534–539)
Lymph node involvement (LNI) is a well-recognized neg-ative factor affecting survival in patients with cancer of
the esophagus and/or gastroesophageal junction (GEJ).1–4
Different characteristics of the lymph node (LN) dissemina-
tion (location, number, lymph node ratio LNR) might affect
survival. More specifically, extension of tumor cells through
the nodal capsule into the fatty tissue—extracapsular LNI—
has been suggested to have a prognostic value on survival for
adenocarcinoma5,6 and for squamous cell carcinoma.7 This
pathologic behavior of the tumor cells extension is related to
a reduced survival and a negative effect on local control of
the tumor.5–7
Because of poor outcomes with surgery alone, an in-
creasing number of patients with locally advanced esophageal
cancer are currently treated with preoperative chemoradiation
therapy (CRT). The largest and most complete meta-analysis
of randomized neoadjuvant treatment trials provides evidence
supporting surgery after induction CRT as the standard of
treatment for fit patients with locally advanced esophageal
cancer, especially in cases of adenocarcinoma.8
After neoadjuvant CRT, a limited number of studies
have explored the prognostic factors of survival for advanced
esophageal cancer. The posttherapeutic stage (ypTNM),9,10
the number of positive LNs11,12, and the LNR13 are considered
as negative prognostic factors for adenocarcinoma. However,
little attention has been paid to the prognosis significance of
the extracapsular LNI after neoadjuvant CRT. Detection and
quantification of extracapsular LNI in the surgical resection
specimen might be helpful not only for staging purposes but
also for individualizing future adjuvant strategies.
The aim of this study was to assess the prognostic value
of the extracapsular LNI in a consecutive series of patients
treated with neoadjuvant CRT followed by standardized
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transthoracic esophagectomy. The relation between extracap-
sular LNI with histologic types and the number of positive
LNs was investigated. Disease-free survival (DFS) was ana-
lyzed according to the nodal status, with special emphasis on
intracapsular and extracapsular involvement, and the invad-
ed/resected LNR.
METHODS
Patients
This retrospective study was conducted according to
the current regulations for clinical research in France. There
was no intent of research at the time of data collection, and all
tests were proposed in the framework of medical care, with a
presumed individual benefit for the patients. Patient charts
were identified by screening a database into which data had
been entered prospectively for any patient undergoing esoph-
ageal resection for cancer at our department.
Between January 1996 and December 2006, a consec-
utive series of 270 patients underwent esophagectomy for a
malignancy of the esophagus or GEJ. Among them, 94
patients who presented with a tumor staged IIB (n  17) and
III (n  77) received neoadjuvant CRT followed by a
transthoracic en-bloc esophagectomy with extended two-field
lymphadenectomy. There were 81 men and 13 women, with
a mean age of 60  9 years. Histology was squamous cell
carcinoma in 46 patients and adenocarcinoma in 48 patients.
Neoadjuvant therapy consisted of two (range 2–6) sessions of
the association 5-fluorouracil/cisplatin concomitantly with a
43  8 Gy radiation therapy.
Surgery
Operations were performed with curative intent, i.e., in
the absence of local irresectability and/or distant metastases
(such as tumor positive cervical LNs or irresectable celiac
nodes). The histologic type and the location of the tumor
dictated the choice of the surgical technique. On this basis, 63
Ivor-Lewis esophagectomies and 31 MacKeown esophagec-
tomies were performed. All patients underwent gastric tube
reconstruction in the posterior mediastinum. The esophagus
was resected en-bloc with all (peri) esophageal tissue in the
mediastinum, including the thoracic duct, azygos vein, ipsi-
lateral mediastinal pleura, upper and lower mediastinal LNs.
The abdominal lymphadenectomy included LNs of the he-
patic artery, celiac trunk, splenic nodes, and nodes at the
origin of the left gastric artery. The surgeon separately
marked the LNs by location, and these nodes were analyzed
separately by the pathologist.
Resected Specimen
The resected specimen was carefully palpated by the
pathologist, and palpable LNs were removed and evaluated.
The posttherapeutic pathologic stage (ypTNM), differentia-
tion grade, longitudinal and circumferential clearances, total
number of removed LNs, and total number of positive LNs,
including their location, were recorded. Larger LNs were
bisected and routine hematoxylin and eosin staining was
performed using a standardized protocol. No additional im-
munohistochemical staining techniques to detect micrometas-
tases were used. An experienced pathologist reexamined all
positive LNs to assess extracapsular LNI. Extracapsular LNI
was defined as metastatic neoplastic tissue extending through
the nodal capsule into the perinodal fatty tissue and breaking
the LN capsula (Figure 1). Deposits of metastatic tumor cells
in the periesophageal fat without a recognizable LN were
considered as extracapsular LNI. A desmoplastic reaction led
the pathologist to reexamine the specimen to identify an
extracapsular LNI.
Statistical Analysis
All patients were seen at the outpatient clinic at inter-
vals of 3 to 4 months during the first 2 years and every 6
months afterward. For patients lost to medical follow-up,
missing data were obtained by consulting the City Hall
registry. Statistical analysis included the Student’s t test, the
2 test, and the Fisher’s exact test as appropriate. Survival
was measured from the date of operation, and survivorship
was calculated according to the Kaplan–Meier method. Sur-
vival curves were calculated from the time of surgery to death
from any cause or to the time of the last follow-up visit (at
which time data were censored). Disease-free survival was
counted up to the time of first relapse or death from any cause
or up to the time of the last visit without a previous relapse.
Survival and DFS curves were drawn up using the Kaplan–
Meier method excluding the in-hospital mortality. DFS was
analyzed according to the nodal status, with special emphasis
on intracapsular and extracapsular involvement, and the in-
vaded/resected LNR. Differences between curves were tested
by the log-rank test. Cox logistic regression was used includ-
ing uni- and multivariate analysis. Variables with a p value
0.2 were included in the multivariate analysis. Logistic
regression was used to identify predictive clinical factors
affecting development of extracapsular LNI. P values below
0.05 were considered to indicate statistical significance.
FIGURE 1. Extracapsular lymph node involvement (LNI).
Extracapsular extension was defined as metastatic neoplastic
tissue extending through the nodal capsule into the peri-
nodal fatty tissue and breaking the lymph node capsula.
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DataSoftware used included Microsoft Excel (Microsoft
Corporation, Redmond, WA) and SPSS 13.0 (SPSS Inc,
Chicago, IL) statistical software.
RESULTS
Number of Lymph Nodes
Sixty-two patients were considered as N0 status (66%).
LNI was identified in 32 patients (34%). Among these 32
patients, 19 had an intracapsular LNI (60%) and 13 had a
documented extracapsular LNI (40%). A total number of
1778 LNs was resected and examined in the 94 patients
(mean 18.9  11 LNs/patient). Metastasis was detected in
120 LNs (7%). Tumor growth beyond the LN capsule was
identified in a total of 49 LNs (41% of the positive nodes).
Extracapsular LNI was confined to only one LN in 6 of the 13
patients (46%). The frequency of extracapsular LNI was
significantly correlated with the number of positive nodes
(Figure 2, p  0.01).
Outcome and Survival
The in-hospital mortality rate was 10.5% (10 of 94
patients): 6 of 62 for N0 patients, 1 of 19 for ICLNI, and 3 of
13 for ECLNI. At the end of the study period, 60 patients
were free of disease. Of the 24 patients who suffered from a
recurrent disease, 13 patients (55%) had hematogenous re-
currence and 11 patients (45%) had locoregional recurrence.
The pattern of recurrence was not significantly different between
patients with and without extracapsular LNI (Table 1).
Five-year DFS rates, excluding the in-hospital mortal-
ity, were 46, 36, and 11% in N0 patients (n  56), intracap-
sular LNI patients (n  18), and extracapsular LNI patients
(n 10), respectively (p 0.002) (Figure 3). In the subgroup
of intracapsular LNI patients, survival was dictated by the LNR.
Intracapsular LNI patients with an LNR 0.1 (n  12) and N0
patients had similar 5-year DFS figures (44 versus 46%, p 
0.95). Intracapsular LNI patients with an LNR beyond 0.1 (n
6) and extracapsular LNI patients also showed similar DFS rates
(18 versus 11%, p  0.69) (Figure 4). According to the histo-
logic type, there were no prevailing differences for adenocarci-
noma or for squamous cell carcinoma.
Survival was not affected by the number of extracap-
sular LNI. Patients with only one positive LN had the same
survival rate compared with patients with two or more nodes
with extracapsular LNI. The location of the extracapsular
breakthrough (peritumoral versus distant) seemed not to af-
fect survival (p  0.41). The median of DFS was 12 months
when the extracapsular LNI was in a peritumoral location.
The median was 9 months when extracapsular LNI was
distant from the esophageal tumor.
TABLE 1. Pattern of Recurrence
N0
n  56
Intracapsular LNI
n  18
Extracapsular LNI
n  10
Free of disease 43 (76%) 12 (66%) 5 (50%)
Locoregional
recurrences
7 (12.5%) 2 (11%) 2 (20%)
Abdominal 2 0 1
Chest 4 2 0
Neck 1 0 1
General recurrence
(solid organ)
6 (11%) 4 (22%) 3 (30%)
The in-hospital mortality was excluded.
Of the 24 patients who suffered from a recurrent disease, 13 patients (55%) had
haematogenous recurrence and 11 patients (45%) had locoregional recurrence.
The pattern of recurrence was not statistically different between N0, intracapsular
LNI, and extracapsular LNI patients.
LNI, lymph node involvement.
FIGURE 2. Correlation between the num-
ber of positive lymph nodes with the num-
ber of nodes with an extracapsular LNI. The
number of lymph nodes with extracapsular
involvement was significantly correlated
with the number of positive nodes (p 
0.01, R  0.80).
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Multivariate Analysis
Eleven factors were thought to affect the DFS and were
included in the univariate analysis excluding the in-hospital
mortality. In the multivariate analysis (Cox regression
model), the sole independent predictive factor affecting DFS
was extracapsular LNI (HR  3.39, p  0.026) (Table 2).
Eight factors were thought to predict development of
extracapsular LNI and were included in a univariate analysis.
On logistic regression, the number of invaded LN seemed to
be the sole significant predictive factor for the development
of extracapsular LNI (HR  2.39, P  0.008) (Table 3).
DISCUSSION
Lymphatic dissemination is the most important predic-
tor for survival in patients with cancer of the esophagus or
GEJ.1–4,14,15 The probability of lymphatic dissemination in-
creases with the depth of the primary tumor.16,17 The number
of positive LNs, their localization, and the LNR gives impor-
tant prognostic information.18,19 A recent review of literature7
has demonstrated that an extracapsular extension of nodal
metastasis was also a significant prognostic factor for carci-
nomas of different organs, including gastric, esophageal, and
colon cancer.
Only a limited number of studies have been published
on extracapsular LNI in esophageal cancer. In squamous cell
TABLE 3. Uni and Multivariate Analysis for Predictive
Factors of Extracapsular LNI
Hazard Ratio
(CI 95%) p
Univariate
Adenocarcinoma/SCC 2.46 (0.59–10) 0.21
Response to neoadjuvant therapy 0.34 (0.06–1.7) 0.19
Resection R0/R1–R2 0.25 (0.02–3) 0.27
pT Stage 1.48 (0.85–2.5) 0.16
Neural invasion 5.91 (0.85–40) 0.094
Number of invaded LN 2.81 (1.6–4.8) 0.0001
Number of resected LN 0.99 (0.94–1.05) 0.87
Distant/peritumoral LNI 5.3 (2.1–13) 0.0003
Multivariate
Response to neoadjuvant therapy 0.8 (0.02–78) 0.94
pT stage 1.4 (0.7–2.8) 0.356
Neural invasion 0.55 (0.02–11) 0.703
Number of invaded LN 2.39 (1.2–4.5) 0.008
Distant/peritumoral LNI 1.8 (0.5–6.8) 0.345
Clinical factors with a p value 0.2 were included in the multivariate analysis.
On the logistic regression model, the sole independent predictive factor of extra-
capsular LNI is the number of invaded LN.
LNI, lymph node involvement; CI, confidence interval; SCC, squamous cell
carcinoma.
FIGURE 3. Disease-free survival according to extracapsular
or intracapsular LNI. The in-hospital mortality was excluded.
Five-years disease-free survival rates were 46, 36, and 11%,
respectively, in N0 patients (n  56), intracapsular LNI pa-
tients (n  18), and extracapsular LNI patients (n  10)
(Log-rank test: p  0.002).
FIGURE 4. Disease-free survival according to lymph node
ratio (LNR). In the subgroups of patients with intracapsular
LNI, survival was dictated by the LNR. Intracapsular LNI pa-
tients with an LNR 0.1 had a similar 5-year DFS rate as N0
patients (44 versus 46%, p  0.95). Intracapsular LNI pa-
tients with an LNR 0.1 had a similar DFS rate as extracap-
sular LNI patients (18 versus 11%, p  0.69).
TABLE 2. Uni and Multivariate Analysis for Factor Affecting
Disease-Free Survival
Hazard Ratio
(CI 95%) p
Univariate
Adenocarcinoma/SCC 1.13 (0.55–2.33) 0.720
Response to neoadjuvant therapy 0.88 (0.4–1.8) 0.73
Resection R0/R1–R2 3.2 (0.59–17.3) 0.175
pT Stage 1.09 (0.8–1.4) 0.48
Lymph node involvement (LNI) 0.4 (0.18–0.87) 0.021
Extracapsular LNI 0.14 (0.04–0.49) 0.001
Neural invasion 0.154 (0.02–1.06) 0.058
Lymph node ratio 4 (1.21–13.1) 0.022
Number of invaded LN 1.13 (1.01–1.26) 0.026
Distant/peritumoral LNI 1.68 (1.1–2.5) 0.016
Differentiation Grade 0.07–2 0.29
Multivariate
Resection R0/R1–R2 0.59 (0.1–2.2) 0.439
Lymph node involvement (LNI) 0.56 (0.06–5.1) 0.617
Extracapsular LNI 3.9 (1.1–13) 0.026
Neural invasion 3.4 (0.7–15) 0.105
Lymph node ratio 0.4 (0.01–8.8) 0.564
Number of invaded LN 1.01 (0.8–1.2) 0.87
Distant/peritumoral LNI 1.6 (0.4–5.8) 0.443
The in-hospital mortality was excluded.
Clinical factors with a p value 0.2 were included in the multivariate analysis.
At multivariate analysis (Cox regression model), the sole independent predictive
factor affecting disease-free survival was extracapsular LNI.
LNI, lymph node involvement; CI, confidence interval; SCC, squamous cell
carcinoma.
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carcinoma of the esophagus, Tachikawa et al.20 analyzed an
inhomogeneous cohort of patients (with or without neoadju-
vant CRT). They concluded that the prognosis was signifi-
cantly worse in patients with extracapsular disease, irrespec-
tive of other pathologic factors. In adenocarcinoma of the
esophagus, Lerut et al.5 included patients with a T3 adeno-
carcinoma of the esophagus or GEJ. Within this uniform
group of 195 patients treated with surgery alone, extracapsu-
lar LNI was a negative prognostic indicator affecting sur-
vival. Moreover, extracapsular LNI was independent of the
number of positive LNs which was shown to be an additional
negative factor. Lagarde et al.6 also reported the negative
impact of the extracapsular LNI on survival in a consecutive
series of 266 LN-positive patients treated with surgery alone
for adenocarcinoma of the distal esophagus or GEJ. The extra-
capsular LNI together with LNR and pT-stage were independent
prognostic parameters for survival in LN-positive patients.
Patients who received preoperative CRT for advanced
esophageal cancer and underwent subsequent surgery, the
posttherapy pathologic status (ypTNM),9–11 the number of
positive LNs, and the LNR are independent prognostic fac-
tors affecting survival.11–13 Surprisingly, despite the well-
known effect of extracapsular LNI in adenocarcinoma of
the esophagus, little attention has been paid to this patho-
logic feature after neoadjuvant CRT and according to the
histologic type.
Our results show a significant difference in DFS de-
pending on whether LN involvement is intracapsular or
extracapsular for advanced esophageal cancer previously
treated with neoadjuvant CRT. The extension of tumor cells
through the nodal capsule is not rare and may concern
approximately 40% of the LNs-positive patients. For patient
with an intracapsular LNI, the prognosis was dictated by the
LNR. The extracapsular LNI acted as an independent nega-
tive factor affecting the DFS in our Cox logistic regression
model. According to the histology, the difference did not
appear significant for adenocarcinoma or for squamous cell
carcinoma, probably because of the small number of patients.
The progression from one node with extracapsular
involvement to two or more LNs had no significant impact on
survival in our study. However, a clear correlation existed
between the number of positive LNs and the number of LNs
with extracapsular extension, reflecting a locally aggressive
behavior of the tumor cells through the capsula. Lagarde et
al.6 have shown that patients with two or more LNs with
extracapsular disease have a very limited chance for definite
cure after surgical therapy, and considered extracapsular LNI
as highly lethal biologic behavior of the tumor. They pro-
posed a theoretical explanation, the so-called “metastases of
metastases,” whereby extracapsular disease can generate new
hematogenous metastases. Our study was not powered enough
to suggest that the localization of the extracapsular LNI might be
an element affecting the survival. Respective median values of
DFS were 12 months when the extracapsular LNI was in a
peritumoral location and 9 months when extracapsular LNI was
distant from the esophageal tumor (p  0.41).
Previous studies have suggested that the incidence of
the extracapsular LNI was higher in patients who underwent
a transthoracic resection.6 This can be explained by the fact
that more LNs are removed by transthoracic esophagectomy
than through a transhiatal approach. To avoid this confound-
ing criterion, only patients who underwent a transthoracic
esophagectomy were included in this study to obtain a ho-
mogeneous cohort of patients with a standardized surgical
approach. The mean number of removed LNs was 18 LNs per
patient, thus reflecting adequate lymphadenectomy with ac-
curate postoperative staging.21 These results plead for an
extensive LN dissection. This is in accordance with a previ-
ous report on the optimal extent of lymphadenectomy for
adenocarcinoma.22–24 The more LNs are removed, better are
staging and survival.
Detection and quantification of extracapsular LNI in the
surgical resection specimen might be helpful to individualize
postoperative therapeutic strategies in the adjuvant setting.
Our results suggested that in the subgroup of patients with
intracapsular LNI, outcome is dictated by the LNR. Survival
of patients with intracapsular LNI and an LNR 0.1 is
similar to survival of patients with extracapsular LNI,
whereas survival of patients with intracapsular LNI and an
LNR 0.1 is similar to survival of N0 patients. On the basis
of the present study, one may hypothesize that adjuvant
therapies are expected for patients with an extensive LN
disease, i.e., extracapsular LNI or with an intracapsular LNI
with an LNR 0.1. In contrast, abstention and surveillance
seem sound for patients with intracapsular LNI and an LNR
0.1, as for N0 patients. These statements deserve their
prospective evaluation.
To facilitate a tailored approach in the neoadjuvant
setting, it would be necessary to discriminate preoperatively
between positive nodes with and without extracapsular LNI.
In this respect, the diagnostic accuracy of endosonography,
computer tomography, and magnetic resonance imaging has
only been tested in limited studies, without convincing results
so far.25–27 The effect of preoperative CRT on the presence
and extent of extracapsular LNI remains unclear, because
these studies did not include patients who received such
therapy. Soon others modalities, such as positron-emission
tomography (PET), may be able to help distinguish LNI with
or without extracapsular disease. However, even after intro-
ducing PET scan, accuracy of LN staging is only 73.8%.5 The
limit of this promising technique is that fluorodeoxyglucose
-PET cannot rule out residual microscopic diseases. In con-
trast, surgery should remain indicated even if the post-CRT
imaging modalities show positive hyperfixation.
For other malignancies, such as breast cancer, extra-
capsular LNI is an important factor included in the TNM
classification as a specified subcategory. For esophageal can-
cer, some authors have pleaded for a revised staging system,
including not only the number of positive nodes and the LNR,
but also the presence of an extracapsular LNI.5,27–30 Recently,
Lagarde et al.31 elaborated a prognostic nomogram to predict
disease-specific survival after esophagectomy, including the
T stage, the LNR, and the extracapsular LNI. The use in
clinical practice of this simple model was more reliable than
the current TNM staging. The LN status (intracapsular versus
extracapsular) should be routinely incorporated in every pa-
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thology report in addition to the number of involved LNs and
the LNR. Thus, the posttherapeutic ypTNM classification
system could be modified to categories such as residual
positive lymph nodes (ypN1) and residual positive lymph
nodes with extracapsular disease (ypN1extracapsular).
CONCLUSION
Despite its small size, this study suggests a difference
in DFS depending on whether LN involvement is intracap-
sular or extracapsular for advanced esophageal cancer treated
with neoadjuvant CRT, transthoracic en-bloc esophagectomy,
and two-field lymphadenectomy. Extracapsular invasion ap-
peared as an independent negative prognosticator, the pres-
ence of which seemed related to the number of invaded LN.
Pathologists should be aware of this biologic feature and
should incorporate it into every postoperative pathologic
report. However, these data have to be validated by further
prospective multicenter studies.
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